Evidence Review
Active Compound Identification
The landmark study by Mavric et al. (2008), published in Molecular Nutrition and Food Research, established methylglyoxal as manuka honey's defining antibacterial compound [1]. Analyzing six New Zealand manuka honey samples, the researchers found MGO concentrations ranging from 38 to 761 mg/kg — up to 100-fold higher than in conventional honey samples. Activity was confirmed as peroxide-independent by comparing results before and after catalase treatment, demonstrating that the non-peroxide fraction of manuka honey was responsible for its superior antimicrobial efficacy.
Spectrum of Antibacterial Activity
Carter et al. (2019) conducted the most comprehensive assessment of UMF-graded manuka honeys to date [4]. Testing UMF 5+, 10+, and 15+ honeys against 128 isolates from wound cultures — including S. aureus, E. coli, Pseudomonas aeruginosa, and Enterococcus faecalis — the team determined MIC values using the broth microdilution method. All grades showed antibacterial activity, with higher UMF values producing progressively lower MICs. Notably, UMF 15+ achieved complete growth inhibition against all S. aureus isolates tested, including MRSA strains, at concentrations achievable in wound dressings.
The study also confirmed that the UMF system provides a reliable proxy for MGO concentration and antibacterial efficacy, validating the grading framework used commercially.
H. pylori Inhibition
Al Somal et al. (1994) were among the first to demonstrate manuka honey's efficacy against H. pylori in laboratory conditions [2]. Using gastric biopsy-derived isolates, they showed complete inhibition of visible growth at 5% (v/v) manuka honey over a 72-hour incubation. The antibacterial activity was confirmed as non-peroxide-dependent, consistent with MGO-mediated mechanisms rather than the hydrogen peroxide activity shared with ordinary honey.
McGovern et al. (1999) subsequently reported a small clinical series of three patients with endoscopically confirmed H. pylori infection who incorporated manuka honey as a supplementary measure alongside conventional therapy [3]. While these cases were descriptive rather than randomized, they helped establish clinical interest in manuka honey for gastrointestinal H. pylori management. Larger controlled trials remain lacking; current evidence supports manuka honey as an adjunct rather than a first-line treatment.
Wound Healing and Tissue Regeneration
Niaz et al. (2017), reviewing the tissue regeneration evidence in Current Drug Metabolism, outlined multiple mechanisms by which manuka honey promotes wound healing [5]: MGO and its precursor glyoxal (GO) exert immunomodulatory effects that accelerate the inflammatory-to-proliferative phase transition; honey's low pH and high osmolarity create an inhospitable environment for bacteria while maintaining tissue hydration; and polyphenolic components support fibroblast activity and collagen synthesis.
The review noted that medical-grade manuka honey dressings have demonstrated effectiveness in published case series for diabetic foot ulcers, pressure ulcers, and post-surgical wound dehiscence — often in situations where standard wound care had failed to promote healing.
Biofilm Disruption
A significant and growing body of in vitro evidence demonstrates manuka honey's ability to disrupt established bacterial biofilms — dense communities of bacteria encased in protective polysaccharide matrices that are notoriously resistant to conventional antibiotics. MGO appears to inhibit biofilm formation and penetrate existing biofilms, compromising bacterial signalling (quorum sensing) and reducing biofilm viability [6]. This property is clinically relevant because chronic wound infections and catheter-associated infections frequently involve biofilm-forming organisms.
Safety and Limitations
Manuka honey is generally safe for most adults and children over 12 months. It is contraindicated in infants under 12 months due to risk of botulism spores, as with all honey products. People with bee product allergies should use caution. For diabetic individuals using it internally, the glycaemic impact (manuka honey has a GI of approximately 54–56, similar to other honeys) should be factored into dietary planning.
Clinical evidence for internal use in human trials remains limited primarily to in vitro and small observational studies; the strongest evidence base is for topical wound care applications. Sourcing matters significantly: products should carry UMF or MGO certification from verified New Zealand producers, as the manuka honey market has documented issues with adulteration.